Merck Total Non-Cash Items 2010-2025 | MRK
Merck annual/quarterly total non-cash items history and growth rate from 2010 to 2025. Total non-cash items can be defined as the total of all non-cash charges adjusting Net Income on the Cash Flows Statement
- Merck total non-cash items for the quarter ending March 31, 2025 were $7.492B, a 48.26% decline year-over-year.
- Merck total non-cash items for the twelve months ending March 31, 2025 were $17.663B, a 58.32% decline year-over-year.
- Merck annual total non-cash items for 2024 were $7.492B, a 48.26% decline from 2023.
- Merck annual total non-cash items for 2023 were $14.479B, a 139.32% increase from 2022.
- Merck annual total non-cash items for 2022 were $6.05B, a 59.29% increase from 2021.
Merck Annual Total Non-Cash Items
(Millions of US $) |
| 2024 |
$7,492 |
| 2023 |
$14,479 |
| 2022 |
$6,050 |
| 2021 |
$3,798 |
| 2020 |
$6,401 |
| 2019 |
$5,001 |
| 2018 |
$5,304 |
| 2017 |
$8,860 |
| 2016 |
$8,823 |
| 2015 |
$7,473 |
| 2014 |
$-5,803 |
| 2013 |
$7,672 |
| 2012 |
$7,831 |
| 2011 |
$6,434 |
| 2010 |
$8,533 |
| 2009 |
$-6,392 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.962B |
$64.168B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
